Recently, led by Professor Ma Jun of the Cancer Center of Sun Yat-sen University, the National Cancer Center of Singapore and the Prince of Wales Hospital of Hong Kong formed the Nasopharyngeal Carcinoma Collaborative Group to determine the exact efficacy of induction chemotherapy for the first time in the world. The results were published online in the well-known oncology journal Clinical Cancer Research and selected as the highlight of the current issue. The US guidelines have adjusted the guidelines for the treatment of locally advanced nasopharyngeal cancer. This is the second time in the United States to adjust the guidelines for the treatment of nasopharyngeal carcinoma based on the original research of the Cancer Center of Sun Yat-sen University.
Nasopharyngeal carcinoma is a common head and neck tumor in southern China. In 2017, there were 5,609 new cases of nasopharyngeal carcinoma admitted to the Cancer Center of Sun Yat-sen University. More than two-thirds of patients with nasopharyngeal carcinoma were in the late stage of localization at the time of treatment. At present, the main treatment plan for this group of patients is concurrent chemoradiotherapy, but there are still about 20% of patients with distant metastasis, which is the main reason for treatment failure.
Ma Jun team completed a multi-center phase III clinical trial in 2012, which confirmed for the first time in the world that concurrent chemoradiotherapy combined with adjuvant chemotherapy failed to further improve the efficacy of patients with nasopharyngeal carcinoma, and brought significant vomiting, mucositis and other diseases. The side reaction rewrote the US guidelines for the treatment of nasopharyngeal carcinoma adjuvant chemotherapy. However, how to improve the efficacy based on concurrent chemoradiotherapy needs further study.
In order to finally determine the status of induction chemotherapy in locally advanced nasopharyngeal carcinoma, Ma Jun team again conducted a randomized controlled trial of multi-center three-drug induction chemotherapy (docetaxel + cisplatin + 5-fluorouracil). The study was led by Prof. Ma Jun and Prof. Hong Ming Huang. In collaboration with researchers from Singapore and Hong Kong, 1193 patients in the epidemic area of ​​nasopharyngeal carcinoma were analyzed. It was found that compared with concurrent concurrent chemoradiotherapy, induction chemotherapy combined with concurrent chemoradiotherapy can treat patients. The distant metastasis rate was reduced by 7%, and the 5-year overall survival rate was increased by 6%. It was clarified that induction chemotherapy can be converted into survival benefit by reducing the risk of distant metastasis of local advanced nasopharyngeal carcinoma, and induction chemotherapy was determined in nasopharyngeal carcinoma. Status in treatment.
Based on the above findings, in 2018, the latest US guidelines have increased the induction chemotherapy regimen from Level 3 evidence for 8 years to Level 2A evidence. (Special correspondent Jin Juan)
Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe
FOSHAN PHARMA CO., LTD. , https://www.pharmainjection.com